HiringSelective
59/100
1 relevant signal
PA
AI drug development · New York, United States
Pathos AI
Current work outlook
Pathos AI closed a $237 million Series E round at an approximately $3 billion post-money valuation, led by Bristol Myers Squibb. The company says the capital will expand its Foundry AI platform and advance four clinical-stage oncology assets, including preparation for a registrational study of JSKN-016.
Updated October 23, 2026 · Evidence from public sources
Flags outlook69/ 100Positive
1 verified signal in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityMixed
60/100
1 relevant signal
Financial healthStronger
66/100
1 relevant signal
InnovationNot enough data
We need a relevant verified event before scoring this dimension.
What moved the outlook
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Pathos AI raises $237 million to scale its oncology platform and clinical pipeline
Pathos AI closed a $237 million Series E round at an approximately $3 billion post-money valuation, led by Bristol Myers Squibb. The company says the capital will expand its Foundry AI platform and advance four clinical-stage oncology assets, including preparation for a registrational study of JSKN-016.
Employee impact
Read full analysis →The round gives Pathos substantial capital for platform and clinical execution, which can support hiring across AI, data, clinical development and operations. Candidates should still distinguish between durable platform roles and positions tied to a single drug program, because clinical milestones can rapidly change budgets.